Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Intronic DNA variants in EZH2 and GATA2 predict treatment-free remission in chronic myeloid leukemia patients from the destiny trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SPShaun PattersonRCRichard E. ClarkHJHeather G. Jørgensen

Discussion

Loading...

Member takes

Overview

Analysis finds intronic variants in the EZH2 and GATA2 genes predict treatment-free remission in CML, suggesting new genomic implications.

Key Points

  • This research aims to identify genetic variants associated with treatment-free remission in chronic myeloid leukemia (CML) patients.
  • Analyzed bone marrow-derived DNA from participants in the DESTINY trial via next generation sequencing.
  • Studied variants in genes associated with clonal hematopoiesis related to treatment-free remission.
  • Conducted multivariate regression analysis to identify predictive factors for molecular recurrence.
  • Variants in EZH2 and GATA2 are positively associated with treatment-free remission in CML patients.
  • Multivariate regression identified EZH2 c.118-4del and GATA2 c.1018-19C>T as strong predictors of sustained treatment-free remission.
  • Patients with DNMT3A variants showed the poorest molecular recurrence-free survival.

Cite This Study

Patterson et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3e9https://doi.org/10.1182/blood-2025-5558
View Full Paper
Ask AI
Bookmark
Share